In the long effort to extend life for patients with limited-stage small-cell lung cancer, a large clinical trial found that adding immunotherapy to standard treatment did not improve survival — yet within that disappointment, a quieter discovery emerged: how radiation is timed may shape not just how long patients live, but how fully they recover their sense of living. The NRG-LU005 trial, enrolling 544 patients across multiple treatment arms, revealed that those receiving radiation twice daily reported more favorable quality-of-life trajectories in the months following treatment, a finding tha
Twice-daily radiation shows QOL benefits in lung cancer trial despite immunotherapy miss
Patients with limited-stage small-cell lung cancer experienced treatment-related quality of life declines during chemoradiation, though improvements were observed post-treatment.